Mike Mensinger - 29 Jan 2025 Form 3 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Product Officer
Signature
/s/ Stephen Feider, Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
29 Jan 2025
Net transactions value
$0
Form type
3
Filing time
29 Jan 2025, 21:41:21 UTC
Next filing
03 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBNX Series D Preferred Stock 29 Jan 2025 Class B Common Stock 15,107 Direct F1, F2
holding BBNX Class B Common Stock Warrant (right to buy) 29 Jan 2025 Class B Common Stock 10,575 $0.0200 Direct F2
holding BBNX Employee Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 236,553 $5.10 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D Preferred Stock (the "Preferred Stock") is convertible into shares of Class B Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock will convert into the number of shares of Class B Common Stock of the Issuer shown in column 3 and subsequently into an equal number of shares of Common Stock of the Issuer. The Preferred Stock has no expiration date.
F2 In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the IPO.
F3 One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.